Physician patterns of metabolic screening for patients taking atypical antipsychotics: A retrospective database study

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 8, Issue 4, 2006, Pages 220-223

  Motsinger, Charles ^a   Slack, Michael ^a   Weaver, Melanie ^a   Reed, Morgan ^a  

^a Malcolm Grow Medical Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; LIPID;

ARTICLE; COMMUNITY HOSPITAL; CONTROLLED STUDY; DATA BASE; GLUCOSE BLOOD LEVEL; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MEDICAL EDUCATION; MEDICAL SPECIALIST; METABOLIC DISORDER; PATIENT IDENTIFICATION; PHYSICIAN; PRESCRIPTION; RETROSPECTIVE STUDY; SCREENING TEST;

EID: 33748555516     PISSN: 15235998     EISSN: None     Source Type: Journal    
DOI: 10.4088/pcc.v08n0405     Document Type: Article

References (10)

1. Lehman AF, chair, Workgroup on Schizophrenia. American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. 2nd ed. Available at: http://www.psych.org/psych_pract/treatg/pg/prac_guide. cfm. Accessed October 8, 2004
2. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601
3. Casey DE. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med 2005;118(suppl 2):15S-22S
4. Wirshing DA. Understanding the new and evolving profile of adverse drug effects in schizophrenia. Psychiatr Clin North Am 2003;26:165-190
5. Gardner DM. Modern antipsychotic drugs: a critical overview. CMAJ 2005;172:1703-1711
6. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1154-1166
7. Bystritsky A. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry 2004;65:565-568
8. Stein MB. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am J Psychiatry 2002;159:1777-1779
9. Adityanjee, Schulz SC. Clinical use of quetiapine in disease states other than schizophrenia. J Clin Psychiatry 2002;63(suppl 13):32-38
10. Rocca P. Treatment of borderline personality disorder with risperidone. J Clin Psychiatry 2002;63:241-244